Shearman Mark S 4
4 · Editas Medicine, Inc. · Filed Feb 11, 2022
Insider Transaction Report
Form 4
Shearman Mark S
EVP, Chief Scientific Officer
Transactions
- Award
Common Stock
2022-02-10+31,709→ 73,494 total - Award
Stock Option (right to buy)
2022-02-10+93,398→ 93,398 totalExercise: $17.29Exp: 2032-02-09→ Common Stock (93,398 underlying)
Footnotes (2)
- [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 10, 2023 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 10, 2026.
- [F2]This option was granted on February 10, 2022 and is scheduled to vest over four years in equal monthly installments beginning on March 10, 2022 through February 10, 2026.